Cygnum device added to aortic aneurysm repair surgery
Tests the Cygnum device alongside standard repair in people with abdominal aortic aneurysm.
Key facts
- Who runs it
- Life Seal Vascular Inc.
- Where
- New Zealand1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- First-In-Human Study Evaluating Aneurysm Sac Lining in AAA Patients
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 26 Nov 2025
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- Cygnum Aneurysm Sac Management Device (ASMD)
- Record updated
- 9 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main belly artery) who will have repair through the blood vessels (EVAR). The Cygnum device will be placed along with the standard repair.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Aneurysm sac at least 5.5cm (2.2 in) wide in males and at least 5.0cm (2 in) in females. Maximum blood flow channel 50mm or less. The anatomy must allow EVAR with the commercial devices used. ASA grade 1 to 3 (a fitness score before anaesthesia).
- Earlier treatment
- No earlier surgery or EVAR repair for the aneurysm.
Main reasons for not taking part
- Ruptured, leaking, inflamed or infected aneurysm
- Life expectancy under 2 years
- Heart attack, major heart surgery, mini-stroke or stroke in the 90 days before the procedure
- Serum creatinine 180 µmol/L (2.04 mg/dL) or higher, or a bleeding or clotting disorder
- Pregnant or planning pregnancy, or connective tissue disease such as Marfan Syndrome
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Patient can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent
- Patient is willing to complete the follow-up according to the requirements of the protocol
- Patient AAA anatomy complies with "instructions for use" for commercial EVAR devices used
- ≥18 years old
- Abdominal aortic aneurysm with sac diameter ≥ 5.5cm in males and ≥ 5.0cm in females
- Maximum blood flow luminal diameter ≤ 50mm
- Eligible for endovascular aneurysm repair based on anatomical considerations, such as adequate iliac/femoral access
- Patient is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive
Who cannot take part
- Concomitant Common Iliac Artery aneurysms ≥ 25mm
- Already participating in an investigational drug or device study
- Previous surgical or EVAR repair for AAA
- Myocardial infarction and/or major heart surgery ≤ 90 days prior to the procedure
- Transient Ischemic Attack or stroke ≤ 90 days prior to the procedure
- Unstable angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease ≤ 30 days prior to the procedure
- Known allergy or contraindication to any study device material
- Coagulopathy or uncontrolled bleeding disorder
- Connective tissue diseases (e.g., Marfan Syndrome)
- Aneurysmal or dissected disease of the descending thoracic aorta
- Serum creatinine level ≥ 180 µmol/L
- Life expectancy <2 years
- Ruptured, leaking, inflammatory or mycotic aneurysm
- Unsuitable vascular anatomy that may interfere with device introduction or deployment, in the opinion of the investigator
- Unable or unwilling to comply with study follow-up requirements
- Patients of childbearing potential who are pregnant or planning to become pregnant during the course of the study
- Patient has other medical, social or psychological problems that, in the opinion of the investigator, study involvement would not be in their best interest
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the safety and feasibility of the Cygnum Aneurysm Sac Management Device in patients with abdominal aortic aneurysms treated with endovascular aneurysm repair (EVAR). The main questions it aims to answer are:
Read full original descriptionShow less
1. Is the Cygnum device safe when used adjunctively with standard EVAR endografts? 2. Does it effectively reduce or prevent type II endoleaks by managing the aneurysm sac?
Participants will:
1. Undergo EVAR with adjunctive implantation of the Cygnum device 2. Have follow-up imaging (e.g., CT scans) and clinical assessments to evaluate device position and sac behavior over time
The group in the trial
- Cygnum ASMD ArmTreatment being tested
Treatment: Cygnum Aneurysm Sac Management Device (ASMD)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Aneurysm SaC ManagemENt Device for Abdominal Aortic Aneurysms First-in-Human (ASCEND) Study
- Plain-language title
- Cygnum device added to aortic aneurysm repair surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 December 2025